insights_auto
Outlook: 32.5% bullish·10.0% bearish
Go to analysischevron_right
NVO:NYSE
Novo Nordisk A/S
$ 38.06
arrow_downward
-1.35%(-0.52) 1D
$ 37.94
arrow_downward
-0.32% (-0.12)todayPre-market
Closed: 10-р сарын 13, 16:00:03 (GMT-4) · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for NVO...
Open
$ 38.74
High
$ 38.89
Low
$ 37.98
Mkt. cap
128.51Т
Avg. vol.
13.22 сая
Volume
96.64 мян
Dividend
4.72%
Quarterly dividend
$ 0.45
Ex-dividend date
2026 оны 8-р сарын 14
P/E ratio
9.74
52-wk high
$ 64.16
52-wk low
$ 35.12
EPS
$ 3.91
Beta
0.75
Shares outstanding
3.39 тэрбум
No. of employees
67 мян
Open
$ 38.74
High
$ 38.89
Low
$ 37.98
Mkt. cap
128.51Т
Avg. vol.
13.22 сая
Volume
96.64 мян
Dividend
4.72%
Quarterly dividend
$ 0.45
Ex-dividend date
2026 оны 8-р сарын 14
P/E ratio
9.74
52-wk high
$ 64.16
52-wk low
$ 35.12
EPS
$ 3.91
Beta
0.75
Shares outstanding
3.39 тэрбум
No. of employees
67 мян
News stories
From web sources and news partners
ad-hoc-news.de
·
22 минутын өмнө
BMO cuts target for Novo Nordisk stock to USD 40.00
Foreign Policy Journal
·
1 цагийн өмнө
Eli Lilly (NYSE: LLY), Novo Nordisk (NYSE: NVO), Intuitive Surgical (NASDAQ: ISRG), And Medtronic (NYSE: MDT) Stand Out As Long-Term Healthcare Plays
Traders Union
·
6 цагийн өмнө
India emerges as a key hub in pharmaceutical companies’ anti-obesity business and research strategy
The Motley Fool
·
13 цагийн өмнө
AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?
Profile
Novo Nordisk A/S, doing business as Novo, is a Danish multinational pharmaceutical company. Novo manufactures and markets pharmaceutical products and services, primarily diabetes and obesity medications and devices. The corporation was created in 1989, through a merger of two Danish pharmaceutical companies, which date back to the 1920s.
Novo employs approximately 68,800 people in 80 countries, and markets its products in approximately 170 countries. Novo is controlled by majority shareholder Novo Holdings which holds 28% of its shares and a majority of its voting shares.
Novo is a full member of the European Federation of Pharmaceutical Industries and Associations.
The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo was named the most sustainable company in the world by the business magazine Corporate Knights. It is a leader in the FTSE4Good Index, and the only European company in the top ten.
Novo is the largest pharmaceutical company in Denmark. Wikipedia
About Novo Nordisk A/S
CEOMaziar Mike Doustdar
Employees66.7 мян
Founded1923
HeadquartersBagsværd, Capital Region of Denmark, Дани
SectorPharmaceutical industry
Websitenovonordisk.com